Vaccine developers Pfizer / BioNTech, together with scientists from the University of Texas, evaluated the effectiveness of the drug against the Brazilian strain of coronavirus. They published the results of their research in the New England Journal of Medicine.
Experts, based on blood samples taken from participants in the last stage of clinical trials of the vaccine, who have already received two vaccinations, concluded that antibodies capable of neutralizing the new mutation appeared in the patients' blood. The researchers note that the vaccine copes with the Brazilian and British strains in about the same way, but with the South African strains, it is slightly worse.
Earlier, Rospotrebnadzor said that the Russian vaccine against coronavirus “EpiVacCorona”, developed by the State Scientific Center for Virology and Biotechnology “Vector”, was effective against new strains of SARS-CoV-2. So, experts tested the effectiveness of the drug against the South African, British and Brazilian mutations of the virus.
